{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:29:29Z","timestamp":1792067369964,"version":"4.4.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01 CA177995-01A1"],"award-info":[{"award-number":["R01 CA177995-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Women with atypical hyperplasia and lobular or ductal carcinoma in situ (LCIS\/DCIS) are at increased risk of developing invasive breast cancer. Chemoprevention with selective estrogen receptor modulators or aromatase inhibitors can reduce breast cancer risk; however, uptake is estimated to be less than 15% in these populations. We sought to determine which factors are associated with chemoprevention uptake in a population of women with atypical hyperplasia, LCIS, and DCIS. Women diagnosed with atypical hyperplasia\/LCIS\/DCIS between 2007 and 2015 without a history of invasive breast cancer were identified (N = 1,719). A subset of women (n = 73) completed questionnaires on breast cancer and chemoprevention knowledge, risk perception, and behavioral intentions. Descriptive statistics were generated and univariate and multivariable log-binomial regression were used to estimate the association between sociodemographic and clinical factors and chemoprevention uptake. In our sample, 29.3% had atypical hyperplasia, 23.3% had LCIS, and 47.4% had DCIS; 29.4% used chemoprevention. Compared with women with atypical hyperplasia, LCIS [RR, 1.43; 95% confidence interval (CI), 1.16\u20131.76] and DCIS (RR, 1.54; 95% CI, 1.28\u20131.86) were significantly associated with chemoprevention uptake, as was medical oncology referral (RR, 5.79; 95% CI, 4.80\u20136.98). Younger women were less likely to take chemoprevention (RR, 0.61; 95% CI, 0.42\u20130.87), and there was a trend toward increased uptake in Hispanic compared with non-Hispanic white women. The survey data revealed a strong interest in learning about chemoprevention, but there were misperceptions in personal breast cancer risk and side effects of chemoprevention. Improving communication about breast cancer risk and chemoprevention may allow clinicians to facilitate informed decision-making about preventative therapy. Cancer Prev Res; 10(8); 434\u201341. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-17-0100","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T20:40:15Z","timestamp":1497386415000},"page":"434-441","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma\n                    <i>In Situ<\/i>"],"prefix":"10.1158","volume":"10","author":[{"given":"Meghna S.","family":"Trivedi","sequence":"first","affiliation":[{"name":"1Columbia University, College of Physicians and Surgeons, New York, New York."},{"name":"2Herbert Irving Comprehensive Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin M.","family":"Coe","sequence":"additional","affiliation":[{"name":"3Columbia University, Mailman School of Public Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Vanegas","sequence":"additional","affiliation":[{"name":"1Columbia University, College of Physicians and Surgeons, New York, New York."},{"name":"2Herbert Irving Comprehensive Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Kukafka","sequence":"additional","affiliation":[{"name":"1Columbia University, College of Physicians and Surgeons, New York, New York."},{"name":"3Columbia University, Mailman School of Public Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Crew","sequence":"additional","affiliation":[{"name":"1Columbia University, College of Physicians and Surgeons, New York, New York."},{"name":"2Herbert Irving Comprehensive Cancer Center, New York, New York."},{"name":"3Columbia University, Mailman School of Public Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"2022060815332756700_bib1","article-title":"SEER Cancer Stat Facts: Female Breast Cancer","author":"NIH"},{"key":"2022060815332756700_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","article-title":"Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention","volume":"95","author":"Freedman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib4","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO.2006.09.0217","article-title":"Stratification of breast cancer risk in women with atypia: a Mayo cohort study","volume":"25","author":"Degnim","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060815332756700_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-012-2318-8","article-title":"The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions","volume":"136","author":"Coopey","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022060815332756700_bib6","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/JCO.2005.04.038","article-title":"Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data","volume":"23","author":"Chuba","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060815332756700_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10549-011-1531-1","article-title":"Second events following ductal carcinoma in situ of the breast: a register-based cohort study","volume":"129","author":"Falk","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2022060815332756700_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"2022060815332756700_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022060815332756700_bib10","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"key":"2022060815332756700_bib12","doi-asserted-by":"crossref","unstructured":"Wickerham\u2008DL, Cecchini\u2008RS, Vogel\u2008VG, Costantino\u2008JP, Cronin\u2008WM, Bevers\u2008TB, et al\u2008Final updated results of the NRG Oncology\/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. J Clin Oncol 33,\u20082015(suppl; abstr 1500).","DOI":"10.1200\/jco.2015.33.15_suppl.1500"},{"key":"2022060815332756700_bib13","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060815332756700_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"2022060815332756700_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Margolese","year":"2016","journal-title":"Lancet"},{"key":"2022060815332756700_bib16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"2022060815332756700_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022060815332756700_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-158-8-201304160-00005","article-title":"Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Nelson","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022060815332756700_bib19","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060815332756700_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1940-6207.CAPR-10-0100","article-title":"The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention","volume":"3","author":"Ravdin","year":"2010","journal-title":"Cancer Prev Res"},{"key":"2022060815332756700_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/tbj.12418","article-title":"Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ","volume":"21","author":"Reimers","year":"2015","journal-title":"Breast J"},{"key":"2022060815332756700_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-012-1960-5","article-title":"Willingness to use tamoxifen to prevent breast cancer among diverse women","volume":"133","author":"Kaplan","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022060815332756700_bib23","first-page":"973","article-title":"Relationships among breast cancer perceived absolute risk, comparative risk, and worries","volume":"9","author":"Lipkus","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815332756700_bib24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","article-title":"Racial differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer","volume":"293","author":"Armstrong","year":"2005","journal-title":"JAMA"},{"key":"2022060815332756700_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-114-8-657","article-title":"Psychological and behavioral implications of abnormal mammograms","volume":"114","author":"Lerman","year":"1991","journal-title":"Ann Intern Med"},{"key":"2022060815332756700_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/jwh.2009.1749","article-title":"Knowledge, preventive action, and barriers to cardiovascular disease prevention by race and ethnicity in women: an American Heart Association national survey","volume":"19","author":"Mochari-Greenberger","year":"2010","journal-title":"J Womens Health"},{"key":"2022060815332756700_bib27","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/bcr3468","article-title":"Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention","volume":"15","author":"Korfage","year":"2013","journal-title":"Breast Cancer Res"},{"key":"2022060815332756700_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10549-011-1450-1","article-title":"Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid","volume":"127","author":"Fagerlin","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2022060815332756700_bib29","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med"},{"key":"2022060815332756700_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/07399863870092005","article-title":"Development of a short acculturation scale for Hispanics","volume":"9","author":"Mar\u00edn","year":"1987","journal-title":"Hispanic J Behav Sci"},{"key":"2022060815332756700_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0272989X0102100105","article-title":"General performance on a numeracy scale among highly educated samples","volume":"21","author":"Lipkus","year":"2001","journal-title":"Med Decis Making"},{"key":"2022060815332756700_bib32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2022060815332756700_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ypmed.2004.09.041","article-title":"Factors affecting breast cancer risk reduction practices among California physicians","volume":"41","author":"Kaplan","year":"2005","journal-title":"Prev Med"},{"key":"2022060815332756700_bib34","first-page":"1352","article-title":"Barriers and facilitators to patient-provider communication when discussing breast cancer risk to aid in the development of decision support tools","volume":"2015","author":"Yi","year":"2015","journal-title":"AMIA Annu Symp Proc"},{"key":"2022060815332756700_bib35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"key":"2022060815332756700_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.breast.2014.11.006","article-title":"Acceptance and adherence to chemoprevention among women at increased risk of breast cancer","volume":"24","author":"Roetzheim","year":"2015","journal-title":"Breast"},{"key":"2022060815332756700_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1158\/1940-6207.CAPR-11-0172","article-title":"Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial","volume":"4","author":"Land","year":"2011","journal-title":"Cancer Prev Res"},{"key":"2022060815332756700_bib39","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.14694\/EdBook_AM.2015.35.e50","article-title":"Addressing barriers to uptake of breast cancer chemoprevention for patients and providers","volume":"35","author":"Crew","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022060815332756700_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnci\/djr154","article-title":"Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women","volume":"103","author":"Matsuno","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib41","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/jnci\/djm223","article-title":"Projecting individualized absolute invasive breast cancer risk in African American women","volume":"99","author":"Gail","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"2022060815332756700_bib43","first-page":"624","article-title":"Women's views on chemoprevention of breast cancer: qualitative study","volume":"52","author":"Heisey","year":"2006","journal-title":"Can Fam Physician"},{"key":"2022060815332756700_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pon.547","article-title":"Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer","volume":"10","author":"Cyrus-David","year":"2001","journal-title":"Psychooncology"},{"key":"2022060815332756700_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.14694\/EdBook_AM.2012.32.152","article-title":"Chemoprevention for breast cancer: overcoming barriers to treatment","volume":"32","author":"Brewster","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022060815332756700_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0039-6060(96)80301-1","article-title":"Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer","volume":"120","author":"Smith","year":"1996","journal-title":"Surgery"},{"key":"2022060815332756700_bib47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1370\/afm.284","article-title":"Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump","volume":"3","author":"Taylor","year":"2005","journal-title":"Ann Fam Med"},{"key":"2022060815332756700_bib48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1525-1497.2006.00461.x","article-title":"\"Why take it if you don't have anything?\" breast cancer risk perceptions and prevention choices at a public hospital","volume":"21","author":"Salant","year":"2006","journal-title":"J Gen Intern Med"},{"key":"2022060815332756700_bib49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"2022060815332756700_bib50","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/0272989X15594382","article-title":"My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the Study of Tamoxifen and Raloxifene (STAR)","volume":"35","author":"Holmberg","year":"2015","journal-title":"Med Decis Making"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/10\/8\/434\/2335719\/434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/10\/8\/434\/2335719\/434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:42:30Z","timestamp":1654688550000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/10\/8\/434\/46770\/Chemoprevention-Uptake-among-Women-with-Atypical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-17-0100","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}